TriNetX Expands the Breadth and Depth of its Global Research Network and Real-World Data Set Adding COVID-19 Vaccination Data to Longitudinal Patient Histories

Share this article
Share this article
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that COVID-19 vaccination data is now available within the TriNetX platform and real-world data (RWD) set for clinical and observational research.
Researchers across industry and academia are now equipped to initiate their own studies with de-identified patient populations that have been immunized against COVID-19 with either Pfizer-BioNTech or Moderna COVID-19 vaccines.
This vaccinated population within the TriNetX data set is over 100,000 patients today and is increasing by the thousands daily as healthcare organizations on the TriNetX network refresh their data. As the data is coming from EHRs, it contains unprecedented richness and longitudinality of detailed medical histories for these patients. In addition to studying the vaccinated population, TriNetX enables the research community to study and compare treatments and outcomes of other cohorts of interest, including one million patients diagnosed with COVID-19, and hundreds of millions of patients with representative comorbidities, rare conditions, and special populations.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Brecht Claerhout , Matveyb Palchuk , Bill Stetson , Pfizer , Twitter , National Institutes Of Health , Chief Data Officer , National Institutes , Vice President , Trial Connect , Trinetx , Llc , கேம்பிரிட்ஜ் , கேம்பிரிட்ஜ்ஷைர் , ஒன்றுபட்டது கிஂக்டம் , ர சி து ஸ்டெட்சன் , ஃபைசர் , ட்விட்டர் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , தலைமை தகவல்கள் அதிகாரி , தேசிய நிறுவனங்கள் , துணை ப்ரெஸிடெஂட் , சோதனை இணைக்கவும் , லல்க் ,